Literature DB >> 12915652

Reduced longevity in untreated patients with isolated growth hormone deficiency.

Amélie Besson1, Souzan Salemi, Sabina Gallati, Arthur Jenal, Rudolf Horn, Pia S Mullis, Primus E Mullis.   

Abstract

Increased longevity of hypopituitary dwarf mice and GH- resistant knockout mice appears to be in contrast with observations made in clinical practice. In humans, on one hand hypopituitarism and GH deficiency (GHD) are believed to constitute risk factors for cardiovascular disease and, therefore, early death. But on the other hand, patients with a PROP-1 gene mutation, presenting with a combined pituitary-derived hormonal deficiency, can survive to a very advanced age, apparently longer than normal individuals in the same population. The aim of this study was to analyze the impact of untreated GHD on life span. Hereditary dwarfism was recognized in 11 subjects. Genetic analysis revealed an underlying 6.7-kb spanning deletion of genomic DNA encompassing the GH-1 gene causing isolated GHD. These patients (five males and six females) were never treated for their hormonal deficiency and thus provide a unique opportunity to compare their life span and cause of death directly with their unaffected brothers and sisters (11 males and 14 females) as well as with the normal population (100 males and females). Although the cause of death did not vary between the two groups, median life span in the GH-deficient group was significantly shorter than that of unaffected brothers and sisters [males, 56 vs. 75 yr (P < 0.0001); females, 46 vs. 80 yr (P < 0.0001)]. Therefore, with the wealth of information regarding the beneficial effects of GH replacement and the dramatic findings of this study, GH treatment in adult patients suffering from either childhood- or adult-onset GHD is crucially important.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12915652     DOI: 10.1210/jc.2002-021938

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  49 in total

Review 1.  Hormone replacement therapy and physical function in healthy older men. Time to talk hormones?

Authors:  Manthos G Giannoulis; Finbarr C Martin; K Sreekumaran Nair; A Margot Umpleby; Peter Sonksen
Journal:  Endocr Rev       Date:  2012-03-20       Impact factor: 19.871

Review 2.  The somatotropic axis and longevity in mice.

Authors:  H M Brown-Borg
Journal:  Am J Physiol Endocrinol Metab       Date:  2015-07-28       Impact factor: 4.310

3.  When Anti-Aging Studies Meet Cancer Chemoprevention: Can Anti-Aging Agent Kill Two Birds with One Blow?

Authors:  Noriko N Yokoyama; Andria Denmon; Edward M Uchio; Mark Jordan; Dan Mercola; Xiaolin Zi
Journal:  Curr Pharmacol Rep       Date:  2015-04-14

Review 4.  Growth hormone and its disorders.

Authors:  J Ayuk; M C Sheppard
Journal:  Postgrad Med J       Date:  2006-01       Impact factor: 2.401

Review 5.  Current guidelines for adult GH replacement.

Authors:  Mauro Doga; Stefania Bonadonna; Monica Gola; Sebastiano Bruno Solerte; Giovanni Amato; Carlo Carella; Andrea Giustina
Journal:  Rev Endocr Metab Disord       Date:  2005-01       Impact factor: 6.514

Review 6.  Hormonal regulation of longevity in mammals.

Authors:  Holly M Brown-Borg
Journal:  Ageing Res Rev       Date:  2007-02-20       Impact factor: 10.895

Review 7.  Role of the GH/IGF-1 axis in lifespan and healthspan: lessons from animal models.

Authors:  Darlene E Berryman; Jens Sandahl Christiansen; Gudmundur Johannsson; Michael O Thorner; John J Kopchick
Journal:  Growth Horm IGF Res       Date:  2008-08-16       Impact factor: 2.372

Review 8.  Growth Hormone Deficiency: Health and Longevity.

Authors:  Manuel H Aguiar-Oliveira; Andrzej Bartke
Journal:  Endocr Rev       Date:  2019-04-01       Impact factor: 19.871

Review 9.  Somatotropic signaling: trade-offs between growth, reproductive development, and longevity.

Authors:  Andrzej Bartke; Liou Y Sun; Valter Longo
Journal:  Physiol Rev       Date:  2013-04       Impact factor: 37.312

10.  Growth hormone decreases visceral fat and improves cardiovascular risk markers in women with hypopituitarism: a randomized, placebo-controlled study.

Authors:  Catherine Beauregard; Andrea L Utz; Amber E Schaub; Lisa Nachtigall; Beverly M K Biller; Karen K Miller; Anne Klibanski
Journal:  J Clin Endocrinol Metab       Date:  2008-04-01       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.